Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. by Morvaridi, Susan et al.
UCLA
UCLA Previously Published Works
Title
Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated 
with cancer and chronic pancreatitis.
Permalink
https://escholarship.org/uc/item/4v38p2mc
Journal
Scientific reports, 5(1)
ISSN
2045-2322
Authors
Morvaridi, Susan
Dhall, Deepti
Greene, Mark I
et al.
Publication Date
2015-11-16
DOI
10.1038/srep16759
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRts | 5:16759 | DOI: 10.1038/srep16759
www.nature.com/scientificreports
Role of YAP and TAZ in pancreatic 
ductal adenocarcinoma and in 
stellate cells associated with 
cancer and chronic pancreatitis
Susan Morvaridi1,2, Deepti Dhall3, Mark I. Greene4, Stephen J. Pandol1,2 & Qiang Wang1,2
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a fibrotic and inflammatory 
microenvironment that is formed primarily by activated, myofibroblast-like, stellate cells. Although 
the stellate cells are thought to contribute to tumorigenesis, metastasis and drug resistance 
of PDAC, the signaling events involved in activation of the stellate cells are not well defined. 
Functioning as transcription co-factors, Yes-associated protein (YAP) and its homolog transcriptional 
co-activator with PDZ-binding motif (TAZ) modulate the expression of genes involved in various 
aspects of cellular functions, such as proliferation and mobility. Using human tissues we show that 
YAP and TAZ expression is restricted to the centroacinar and ductal cells of normal pancreas, but 
is elevated in cancer cells. In particular, YAP and TAZ are expressed at high levels in the activated 
stellate cells of both chronic pancreatitis and PDAC patients as well as in the islets of Langerhans 
in chronic pancreatitis tissues. Of note, YAP is up regulated in both acinar and ductal cells following 
induction of acute and chronic pancreatitis in mice. These findings indicate that YAP and TAZ may 
play a critical role in modulating pancreatic tissue regeneration, neoplastic transformation, and 
stellate cell functions in both PDAC and pancreatitis.
Pancreatic cancer is the fourth leading cause of cancer-related death1–3. Pancreatic ductal adenocarci-
noma (PDAC) comprises more than 85% of all pancreatic cancer and has extremely poor prognosis, with 
an overall five-year survival rate at less than 5%2,4. Chronic pancreatitis, a clinical syndrome of persistent 
pancreatic inflammation, is one of the leading risk factors for pancreatic cancer5,6. The normal exocrine 
pancreas primarily consists of acinar cells, which produce digestive enzymes, and ductal cells that form 
the lining of the secretory ductal system. Centroacinar cells are located at the junction between acinar 
cells and the terminal ductal epithelium. In addition, pancreatic stellate cells (PSCs) are myofibroblast-
like cells that are normally quiescent but become activated in damaged pancreas and produce collagen, 
fibronectin and other fibrosis related proteins7,8. Both PDAC and chronic pancreatitis are characterized 
by a fibrotic and inflammatory microenvironment that is dominated by activated stellate cells.
The Hippo-YAP signaling pathway was initially identified as a mechanism involved in regulation 
of organ size and tissue growth and is more recently implicated in playing a role in cell proliferation, 
migration, stem cell self-renewal, and tissue regeneration9–13. In mammalian cells, YAP and its homolog 
TAZ (also known as WW Domain Containing Transcription Regulator 1, or WWTR1) function as tran-
scriptional cofactors and the core of this signaling pathway14. The transcriptional activity of YAP and 
TAZ is subjected to negative regulation by a cascade of phosphorylation events, mediated by Mst1/2 and 
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LATS1/2, leading to cytoplasmic sequestration or ubiquitin-mediated degradation9,10. In particular, YAP 
can be phosphorylated at S127 in a cell density-dependent manner and forms a more stable complex with 
the 14-3-3 proteins, thereby becoming retained in the cytoplasm15–17. YAP phosphorylation is mediated 
by signaling events are initiated from cell surface adhesion molecules, including E-cadherin-like mole-
cules and proteins of the adherens junction and tight junction protein complexes9,10. In addition, YAP 
activity can be inhibited through the interactions with angiomotin (AMOT) family proteins, which lead 
to localization and sequestration of the YAP protein to tight junction9,18,19, or through interactions with 
PTPN1410,20–23, a non-receptor tyrosine phosphatase that is localized to the tight junction of epithelial 
cells9,24–26.
Here, we provide evidence that YAP and TAZ are present in normal pancreatic centroacinar and 
ductal cells, and are up regulated in pancreatic cancer cells and in the activated pancreatic stellate cells 
that define the stromal environment of chronic pancreatitis and pancreatic cancer. We also find signif-
icant increase in the cells of the islets of Langerhans in chronically inflamed but not normal pancreas. 
Moreover, YAP levels are increased in experimental acute and chronic pancreatitis. Our results support 
the notion that YAP and TAZ deregulation may play a role in pathogenesis of pancreatic diseases.
Results
YAP and TAZ/WWTR1 are primarily expressed in the centroacinar and ductal cells in normal 
human pancreas. We performed immunohistochemistry to examine the expression patterns of YAP 
and TAZ/WWTR1 in normal human pancreatic tissues obtained from four individuals. The YAP expres-
sion patterns resemble those of the centroacinar cells and ductal cells (Fig. 1), the subpopulations of the 
exocrine compartments that are implicated in having certain stem cell properties during tissue regenera-
tion following injury27–32. In these cells, YAP and TAZ show diffused localization and the proteins can be 
found in both nuclei and cytoplasm (Fig. 1). In contrast, YAP is not expressed in acinar cells, or in islets 
of Langerhans (Fig.  1). These expression patterns of YAP were confirmed using three additional anti-
YAP antibodies, including antibodies specific for the S127 phosphorylated form of YAP (Supplemental 
Figure S1). Furthermore, we observed similar centroacinar/ductal localization patterns for TAZ (Fig. 1).
Figure 1. Immunohistochemistry analysis of YAP and TAZ/WWTR1 in normal human pancreas. 
(A,B) Immunohistochemistry analysis of normal human pancreatic tissue using anti-YAP antibody (H125); 
Two representative fields of the same sample are shown. Specimens obtained from an additional three 
individuals were also analyzed and shown in Supplemental Figure S2. The islet of Langerhans is indicated. 
Magnification: 20 x, error bar: 100 μ m. (C,D) Immunohistochemistry analysis of normal human pancreatic 
tissue using anti-TAZ/WWTR1 antibody. Two representative fields of the same sample are shown. The islet 
of Langerhans is indicated. Magnification: 20 x, error bar: 100 μ m.
www.nature.com/scientificreports/
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Figure 2. Immunofluorescence staining of YAP in normal human pancreas. (A) annexin A2 (ANXA2) 
(green), carbonic anhydrase II (CA II) (red), DAPI (blue); Magnification: 63 x. Note that ANXA2 is 
expressed in the same cells that are positive of CA II, a marker for pancreatic centroacinar and ductal cells. 
(B) YAP (anti-YAP, H-125) (red) and ANXA2 (green), DAPI (blue). Magnification: 63 x. Note that YAP and 
ANXA2 are co expressed in the same set of cells.
www.nature.com/scientificreports/
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Immunofluorescence studies were carried out to determine whether YAP is co-expressed with estab-
lished markers of centroacinar cells and ductal cells, such as carbonic anhydrase II (CA II)33–35. Similar 
to a previous study36, our study showed that annexin A2 (ANXA2) staining exhibits a pattern indicative 
of centroacinar and ductal cell specific expression (Supplemental Figure S4). In addition, we found that 
ANXA2 is co-expressed with CA II in normal pancreas and thus established it as another marker for 
the centroacinar and ductal cells (Fig.  2A and supplemental Table S1). Moreover, our results clearly 
show co-expression of YAP and ANXA2 in the normal pancreas (Fig. 2B and supplemental Table S1), 
which indicates that YAP expression is primarily restricted to the centroacinar and ductal cells. Notably, 
ANXA2 is predominantly localized to the plasma membrane in these cells, whereas YAP is primarily 
found in the cytoplasm and to a lesser extent in the nuclei (Fig. 2).
YAP and TAZ expression in pancreatic intraepithelial neoplasia, PDAC and chronic pancreatitis. 
Among the PDAC tissues collected from four individual patients, high levels of YAP were detected in 
pancreatic cancer cells that exhibit epithelial morphology (Fig. 3 and Supplemental Figure S2). Similar, 
the levels of TAZ are also elevated in PDAC (Fig. 4). In particular, YAP and TAZ can be detected in cells 
that show characteristics of pancreatic intraepithelial neoplasia (PanIN) (Figs 3 and 4), which represent 
the majority of the early neoplastic lesions37,38. Both YAP and TAZ show a more prominent nuclear 
localization pattern, which is consistent with the notion that these proteins are functionally activated. 
Moreover, a fraction of stromal cells are also stained positive for YAP and TAZ (Figs 3 and 4).
Notably, in tissues of chronic pancreatitis, YAP and TAZ levels are expressed in a sub-population of 
stromal cells (Fig. 5 and Supplemental Figure S3). YAP and TAZ levels also appear to be elevated in the 
islets of Langerhans in the chronic pancreatitis tissue in contrast to normal pancreas. The localization is 
predominantly nuclear in the islet cells (Fig. 5 and Supplemental Figure S3).
YAP is expressed at high levels in activated stellate cells associated with chronic pancreatitis 
and PDAC. We noted that, in both chronic pancreatitis and pancreatic cancer tissues, the stromal 
cells stained positive for YAP and TAZ show morphology of stellate cells, which are characterized by 
elongated nuclei and branching cell body (Figs 3,4 and 5; Supplemental Figures 2 and 3). By immuno-
fluorescence, we found that YAP can be detected in the same set of cells that are stained positive for 
Figure 3. YAP expression in human pancreatic cancer tissues. (A–D) YAP staining (anti-YAP antibody, 
H125) in PDAC #1 tissue. Specimens obtained from an additional three PDAC individuals were also 
analyzed and shown in Supplemental Figure 2. Representative images of four different fields of the same 
sample are shown. Note that YAP can be detected in stellate cells (arrows), cancer cells (arrowheads) and in 
structures showing morphology of early PanIN or normal ducts (asterisks). Magnification: 20 x, error bar: 
100 μ m.
www.nature.com/scientificreports/
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Figure 4. TAZ/WWTR1 expression in human pancreatic cancer tissues. (A–D) TAZ/WWTR1 in PDAC tissues 
(arrows: stellate cells; arrowheads: cancer cells; asterisks: PanIN or ducts with normal morphology). Representative 
images of four different fields of the same sample are shown. Magnification: 20 x, error bar: 100 μ m.
Figure 5. YAP and TAZ/WWTR1 expression in human chronic pancreatitis (CP) tissues. (A) Chronic 
pancreatitis tissue isolated from CP patient #1, stained using anti-YAP antibody (H125). Specimens obtained 
from an additional three individuals were also analyzed and shown in Supplemental Figure S3. Representative 
images are shown. (B) Chronic pancreatitis tissue (CP#1) stained using anti-WWTR1/TAZ antibody. The 
arrowheads indicate expression of YAP or TAZ in stellate cells. Magnification: 20 x, error bar: 100 μ m.
www.nature.com/scientificreports/
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Figure 6. Immunofluorescence analysis of YAP in stellate cells of human PDAC tissues. (A) YAP (red) 
and α -SMA (green), and DAPI (blue). Note that YAP can be detected in both the cancer cells and the 
stromal cells. Magnification: 20 x. (B) Image of PDAC tissue stained in the same way as in (A), showing a 
field predominantly of stellate cells. Magnification: 63x.
www.nature.com/scientificreports/
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Figure 7. Co-expression of YAP and annexin A2 (ANXA2) in human PDAC tissues. (A) YAP (red), 
ANXA2 (green), and DAPI (blue). Note that YAP and ANXA2 are co-expressed in the cancer cells. (B) 
ANXA2 (red), α -SMA (green), and DAPI (blue). Note that the field shows predominantly stellate cells. 
Magnification: 63 x.
www.nature.com/scientificreports/
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α -SMA, a marker for activated stellate cells. While α -SMA is localized to the cytoplasm in these cells, 
YAP can be found in both the nuclei and the cytoplasm (Figs 6 and 7). Thus, our results indicate that 
YAP is expressed in the stellate cells of both chronic pancreatitis and PDAC. Interestingly, ANXA2 is 
co-expressed with YAP in activated stellate cells (Fig. 7) and in cancer cells (Fig. 8).
YAP is up regulated in Kras G12D mutant-mediated pancreatic intraepithelial neoplastic 
lesion and in experimental acute and chronic pancreatitis. The Kras gene is frequently mutated 
in pancreatic cancer patient and is thought to contribute to development of early neoplastic lesions4. In 
particular, the G12D mutation of Kras leads to abnormal activation of Kras functions and can promote 
development of PanIN in the Pdx1-Cre/LSL-KrasG12D (KC) transgenic mice, in which the KrasG12D 
can be induced in pancreatic cells via Pdx1 promoter-mediated expression of Cre recombinase39. We 
therefore examined YAP and TAZ expression patterns in these animals. Consistent with previous report39, 
at the age of seven month, the pancreata of KC mice show extensive areas of PanIN but no PDAC. Our 
IHC studies indicate that, in the control Pdx1-Cre mice, YAP and TAZ exhibit a pattern of expression in 
the ductal cells (Fig. 9A,C). In the KC mice, the overall expression levels of YAP and TAZ are increased 
and both proteins can be detected in the nuclei of PanIN cells, as well as in stellate cells associated with 
the neoplastic lesion (Fig. 9B,D).
We also examined YAP levels in the process of tissue injury and regeneration using a previously 
established mouse model, in which acute or chronic pancreatitis develops upon exposure of mice to 
cerulein6,40–42. In particular, short-term administration of cerulein induces a mild and reversible form of 
acute pancreatitis in mice, characterized with edema, cellular stress, necrosis, and inflammation6,40,42. Our 
H & E staining confirmed that cerulein induced tissue injury in the pancreas by 8 hours (Fig. 10B,D). At 
this time point, an abrupt increase of YAP expression, with prominent nuclear localization, was detected 
in not only the ductal but also the acinar cells (Fig. 10C,D). YAP expression remains at high levels 3 days 
after the initial induction of injury, when the injured tissue has undergone extensive recovery and shows 
characteristics of acinar-to-ductal metaplasia (ADM) (Fig. 10E,F).
Repeated and prolonged exposure of cerulein induces a form of chronic pancreatitis6,41, which is 
distinguished by development of fibrosis and irreversible tissue degeneration (Fig.  10G). Under this 
Figure 8. Immunofluorescence analysis of YAP in stellate cells of human chronic pancreatitis tissues. 
YAP (red), α -SMA (green) and DAPI (blue). The arrows indicate examples of cells in which YAP and 
α -SMA are co-expressed. Magnification: 63 x.
www.nature.com/scientificreports/
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experimental condition, YAP is up regulated, notably in the nuclei of both the acinar cells and in the 
expanded ductal structures that are frequently present in the chronic lesions (Fig. 10H).
Discussion
In this study, we characterized YAP-expressing cells using cell population-specific markers (i.e. alpha-SMA 
for activated stellate cells, and CAII and Anxa2 for centroacinar and ductal cells) in normal and diseased 
pancreas. Our results indicate that YAP and TAZ expression in centroacinar and ductal cells of normal 
human pancreas. The centroacinar and ductal cells exhibit the capacity as multi-lineage pancreatic pro-
genitors that are important for tissue repair and regeneration27–32. These cells express several markers pre-
viously associated with the progenitor phenotypes in embryonic pancreas and other tissues, such as Sca1, 
Sdf1, c-Met, nestin, and SOX943–45. In particular, SOX-9 has been identified as a marker of pancreatic 
centroacinar and ductal cells and is crucial for development and regeneration44,46–48. The functional link-
age between YAP and SOX9 has been revealed by a recent study49. Moreover, acinar cells exhibit regen-
erative potentials and undergo acinar-to-ductal metaplasia following injury of exocrine pancreas50–52. 
In this process, the acinar cells transdifferentiate to a precursor state that demonstrates phenotypes of 
ductal cells. Indeed, recent studies indicate that YAP signaling pathway is essential for development of 
the pancreas and activation of YAP in the adult pancreas results in pancreatitis-like phenotypes53,54. YAP 
and TAZ have been implicated in stem cell functions in other tissues, such as the small intestine11,55–59, 
the lung60,61, the liver62, the skin63, the bone64, or in developing embryos12,65. In the current study, we 
observed up regulation of YAP in both acinar and ductal cells, following induction of acute or chronic 
pancreatitis by extensive cerulein exposure. Thus, these findings suggest that YAP and TAZ may repre-
sent a set of new markers for the “stem-cell” like phenotype and play a role in modulating progenitor cell 
functions in pancreatic regeneration in events of pancreatic injury, such as acute or chronic pancreatitis.
We show that YAP and TAZ are expressed predominantly in the nuclei in the epithelial compartment 
of PDAC, which is in agreement with the notion that these proteins are functionally activated. Of note, 
nuclear localization patterns of YAP and TAZ expression can be readily detected in cells with morpho-
logical features of PanIN in both human tissues and Kras G12D mutant mice. These observations are 
consistent with the recent report that YAP plays an essential role in the early neoplastic transformation 
in the pancreas using a mouse model of pancreatic cancer66.
Figure 9. Immunohistochemistry analysis of YAP and TAZ in mouse pancreas. Immunohistochemistry 
analysis of mouse pancreatic tissue using anti-YAP antibody (A,B) or anti-TAZ (C,D). Representative images 
are shown. (A,C): tissues isolated from Pdx1-Cre mice; (B,D): tissues isolated from Pdx1-Cre/LSL-KrasG12D 
mice. Examples of cells with up regulation of YAP or TAZ are indicated by arrows (duct-like cells) or 
arrowheads (stellate cells). Magnification: 20 x, error bar: 100 μ m.
www.nature.com/scientificreports/
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We previously show that YAP mediates cancer cell sensitivity to a number of therapeutics, including 
cisplatin, taxol, EGFR tyrosine kinase inhibitor, or small molecule inhibitor of survivin10. More recent 
studies revealed that deregulation of YAP signaling may contribute to acquired resistance to therapeutic 
approaches targeting the signaling events initiated by mutant Kras. For example, YAP overexpression 
enables pancreatic, colorectal, or lung cancer cells to overcome dependency on oncogenic Kras muta-
tions67,68. These findings indicate that YAP may represent an attractive therapeutic target for treatment 
of human pancreatic cancer. It should be noted that a successful targeting strategy conceivably require 
Figure 10. YAP is up regulated in experimental pancreatitis. Left panels: Immunohistochemistry analysis 
of mouse pancreatic tissues using anti-YAP antibody; Right panels: H&E staining. Representative images are 
shown. (A,B): control; (C,D): Eight hours after initial cerulein-induction of acute pancreatitis; (E,F): Three 
days after initial cerulein-induction of acute pancreatitis; (G,H): cerulein-induced chronic pancreatitis (CP). 
Note that H&E staining shows cerulein induced tissue damage (D,H) and fibrosis (H). The arrowheads 
indicate examples of cells with up regulation of YAP. Magnification: 20 x, error bar: 100 μ m.
www.nature.com/scientificreports/
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simultaneous disabling YAP and WWTR1, due to their functional redundancy and the commonly over-
lapping expression patterns in human pancreatic cancer.
Remarkably, our results show that both YAP and TAZ are expressed in the pancreatic stellate cells 
associated with human pancreatic ductal adenocarcinoma and chronic pancreatitis. In particular, YAP 
and TAZ positive stellate cells are associated with Kras mutant-mediated early neoplastic transformation. 
Activation of PSCs is required to initiate fibrogenesis and chronic pancreatitis8. Progression to chronic 
pancreatitis may occur in patients with metabolic stress in the pancreas attributable to excessive alcohol 
consumption69. PSCs can be activated by growth factor or cytokines released by injured or stressed aci-
nar cells and by various inflammatory cells8. For example, TGF β and CTGF/CCN2) are profibrogenic 
factors that can activate PSCs, resulting in their proliferation, the production and deposition of collagen 
1A1 and pancreatic fibrogenesis8. YAP acts in concert with TGF β signaling and modulates CTGF/CCN2 
expression70. Thus, our finding of YAP and TAZ expression in PSC of chronic pancreatitis and pancreatic 
cancer highlights the potential role of these transcriptional co-factors in modulating the physiological 
and pathological activities of PSC.
Interestingly, we found co-expression of ANXA2 with YAP/TAZ in the centroacinar and ductal cells 
of normal pancreas, as well as in the activated stellate cells of chronic pancreatitis and pancreatic cancer. 
ANXA2 is implicated in multiple functions, including the secretory pathway, tissue regeneration, and 
tumorigenesis. For example, ANXA2 can be localized to the cell surface and mediate the activation of 
plasminogen, which is involved in in thrombolysis, wound healing, angiogenesis, and EMT71–74. In addi-
tion, ANXA2 is overexpressed in pancreatic cancer and may play a critical role in cancer cell invasion 
and metastasis75–77. Clearly it would be of interest to define the functional interactions between ANXA2 
and YAP signaling in both the normal and diseased pancreas, especially in regard to the role in the 
pancreatic stellate cells.
We found that YAP and TAZ are up regulated in the islets Langerhans of chronic pancreatitis tissues. 
Diabetes is a frequent complication in chronic pancreatitis. YAP and TAZ may be involved in regenera-
tion or adaptive response of islets under chronic pancreatitis. A variety of islet cell types have been shown 
to possess the properties of progenitors, such as β -cells78,79 and nestin-positive islet-derived progenitor 
cells80. In this regard, YAP may play a role in defining the self-renewal or the regeneration capacity of the 
progenitor cells. Alternatively, deregulation of YAP signaling may lead to islet dysfunction. For example, 
a recent study showed that MST1/STK4, a mammalian orthologue of Hippo, is activated in beta cells 
in the islets and can induce mitochondrial-dependent apoptosis81. Clearly addition work is needed to 
clarify these possibilities.
In summary, our study demonstrates that while YAP and TAZ expression is limited to the centroac-
inar and intercalated ductal cells in normal human pancreas, these proteins are up regulated in PDAC 
and PanIN, as well as in stellate cells associated with PDAC and chronic pancreatitis. Moreover, we 
found expression of YAP and TAZ in the islets of Langerhans in diseased human pancreatic tissues. 
These findings indicate that YAP and TAZ may be involved in pancreatic tissue regeneration, and that 
deregulation of these proteins may play a role in neoplastic transformation and stellate cell functions in 
both PDAC and pancreatitis.
Methods
Antibodies. The antibodies used in this study include: anti-YAP and anti-phospho S127 YAP (#4912; 
#4911; and #13008, Cell Signaling Technology, Danvers, MA) anti-YAP (H-125), anti-ANXA2 (C-10), 
and anti-CA II (Santa Cruz Biotechnology, Santa Cruz, CA); anti-WWTR1/TAZ and anti α -SMA (Sigma, 
St. Louis, MO); anti-MST1R/RON antibodies (R&D Systems, Minneapolis, MN); horse radish peroxi-
dase-conjugated secondary antibodies against mouse or rabbit were from Dako (Carpentaria, CA). Alexa 
Fluor 488 or 594 conjugated anti-mouse or anti-rabbit antibodies were purchased from Life Technologies 
(Grand Island, NY).
Human Tissues. Formalin-fixed and paraffin-embedded (FFPE) human pancreatic specimens were 
obtained from the Cedars-Sinai Pathology archive and biorepository, and the analyses were carried out 
under protocols approved by the Internal Review Board at the Cedars-Sinai Medical Center (IRB proto-
cols #4201, #28197 and #34086). All experiments were performed in accordance with relevant guidelines 
and regulations.
Transgenic Mice and Experimental Acute and Chronic Pancreatitis. The Pdx1-Cre and 
Lox-Stop-Lox-KrasG12D mice were described previously39. The mice were interbred to create Pdx1-CRE/
LSL-KrasG12D (KC) mice at the Genetics Core of the Cedars-Sinai Medical Center. Pancreata were col-
lected from 7-month old mice, fixed in formalin and embedded in paraffin.
C57BL/6 J mice (B6J) were obtained from the Jackson Laboratory (Bar Harbor, ME). To induce acute 
pancreatitis, the mice were given seven hourly intraperitoneal (IP) injections of cerulein (American 
Peptide Company, Sunnyvale, CA), at a dosage of 50 μ g/kg body weight per injection. The mice subjected 
to injections of PBS served as the control. The mice were sacrificed at the time points as indicated in 
each experiment (ranging from 8 hours to 3 days after the initial injection), and the tissues were collected 
used for further analysis. To induce acute pancreatitis, the mice received two courses of cerulein injection 
www.nature.com/scientificreports/
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per week (with 3–4 days apart) for a total of 5 weeks. Each course of cerulein administration consisted 
of seven hourly intraperitoneal injections of cerulein at a dosage of 50 μ g/kg body weight per injection. 
A separate set of mice will receive sterile saline solution as control. The mice were sacrificed five days 
after the final injection, and the tissues were collected used for further analysis. Pancreata were fixed in 
formalin and embedded in paraffin.
All animal procedures were approved by the Cedars-Sinai Institutional Animal Care and Use 
Committee (IACUC) under protocol number 3935. All experiments were performed in accordance with 
relevant guidelines and regulations.
Immunohistochemistry. For the study of human tissues, a total of 4 sets of specimens, each contain 
normal, PDAC, and chronic pancreatitis tissues, were analyzed. Both human and mouse FFPE pancre-
atic specimens were de-paraffinized, rehydrated, and subjected to antigen retrieval by heating. After 
incubating in blocking solution from VECTASTAIN Elite ABC Kit (Vector Laboratories, Burlingame, 
CA) for 20 minutes, the samples were treated with the primary antibodies for 60 minutes or overnight. 
The sections were then washed three times in PBS, followed by incubation with a secondary antibody 
conjugated with horse radish peroxidase (Dako, Carpentaria, CA) for 60 minutes. The samples were sub-
jected to final washes, and specific stains were developed with ABC reagent for up to 10 minutes, using 
ImmPACT/DAB peroxidase substrate (Vector Laboratories, Burlingame, CA). The slides were mounted 
and scanned using Aperio Scanscope® AT Turbo (Leica Microsystems, Buffalo Grove, IL).
Immunofluorescence and confocal microscopy. The FFPE pancreatic tissue sections prepared on 
glass slides were de-paraffinized, rehydrated, and subjected to antigen retrieval by heating. After incu-
bating in blocking solution (Animal-Free Blocker™ , Vector Laboratories), the sections were stained with 
the primary and secondary antibodies sequentially in phosphate-buffered saline (PBS) containing 0.2% 
Triton X-100. The slides were mounted and analyzed using Leica TCS SP5 confocal microscope (Leica 
Microsystems, Buffalo Grove, IL). For analysis of gene co-expression in the IF study, GraphPAD Prism 
software (GraphPad Software, San Diego, CA, USA) was used to perform Fisher’s exact test using data 
collected in 3 random fields of each immunofluorescence staining sample.
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